Nabitan

Delta-9-THC analogue tested against pain in 1978, with no advantage over placebo.

FranceStatus changing InternationalUnscheduled

C₃₅H₅₂N₂O₃

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

Data sheet

Names

IUPAC name: [5,5-dimethyl-8-(3-methyloctan-2-yl)-2-prop-2-ynyl-3,4-dihydro-1H-chromeno[4,3-c]pyridin-10-yl] 4-piperidin-1-ylbutanoate
Other names: Nabitan [INN] · Nabitanum · Nabutan · Benzopyranoperidine · JO7BOR6B3O

Identifiers

Formula: C₃₅H₅₂N₂O₃
Molar mass: 548.80 g/mol
CAS: 66556-74-9
PubChem CID: 39503(new tab)
InChIKey: MCVPMHDADNVRKF-UHFFFAOYSA-N

Class

Family: ECS modulator (research)

Legal status

France: Status changing
International: Unscheduled

See the legal framework

Updated on 13 October 2026

Receptors and activity

CB1Modulatoraucune constante d'affinité publiée5 out of 100

Bar length shows the relative strength of the interaction, as an indication.

Subjective signature

Calm: 10 out of 100; Relaxation of body and mind; reduced mental noise without marked drowsiness.
Clarity: 3 out of 100; Sustained attention and clear thinking; functional lucidity, not euphoria.
High: 3 out of 100; Euphoria and sensory intensity; altered perception of time and space.
Appetite: 3 out of 100; Stimulation of hunger and of taste appreciation (the “munchies” effect).
Sleep: 5 out of 100; Sedative effect: aids sleep onset and the continuity of deep sleep.

Editorial estimate, not clinical.

Pharmacology

Nabitan, also called benzopyranoperidine, is an analogue of delta-9-THC described in the clinical literature. A double-blind crossover trial published in 1978 compared, in 35 patients with cancer pain, two oral doses, 2 and 4 mg, with codeine (60 and 120 mg) and with placebo: the molecule was no more effective than placebo, and pain perception appeared even increased at both doses. The 2001 systematic review (Campbell et al.) reports the same lack of superiority over placebo. No binding affinity constant for the CB1 or CB2 receptors is published in the sources consulted, and no pharmacokinetic or human safety data were found in those sources.

Key sources.

History

Source: Presented as an analogue of delta-9-THC in the 1978 clinical literature (Jochimsen et al.), and listed among the cannabinoids studied by the 2001 review (Campbell et al.). No source consulted reports it in a plant.

Origin (research tool)

No biosynthetic pathway is known in the sources consulted. Obtained by chemical synthesis, described here by chemical class only: a benzopyrano-pyridine derivative of the tricyclic THC skeleton.

Legal framework

European Union: No harmonised control measure at European Union level was found for this molecule in the sources consulted: control currently rests with national regimes. No marketing authorisation is documented in the sources consulted.
France: Nabitan is not named under any of its names or codes in the ANSM consolidated list of narcotics (updated 16 February 2026). It also does not appear in the INCB Green List 2026. The generic clause for the benzo[c]chromene nucleus (ANSM decision of 22 May 2024) is close to its structure, but its ring A contains a nitrogen atom in place of a carbon of the skeleton: the text does not allow certainty on whether this difference takes it outside the definition. The French status is therefore marked as evolving, without a firm classification.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

References

Structured data

SMILES: CCCCCC(C)C(C)C1=CC2=C(C3=C(CCN(C3)CC#C)C(O2)(C)C)C(=C1)OC(=O)CCCN4CCCCC4
InChIKey: MCVPMHDADNVRKF-UHFFFAOYSA-N

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.